56,776 Shares in Kenvue Inc. $KVUE Acquired by Insight Advisors LLC PA

Insight Advisors LLC PA acquired a new position in shares of Kenvue Inc. (NYSE:KVUE) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 56,776 shares of the company’s stock, valued at approximately $1,003,000.

Other large investors also recently added to or reduced their stakes in the company. BlackRock Inc. acquired a new stake in shares of Kenvue in the 2nd quarter worth $2,882,279,000. Pentwater Capital Management LP purchased a new position in shares of Kenvue during the 2nd quarter worth $977,094,000. HBK Investments L P boosted its position in shares of Kenvue by 33.3% during the 2nd quarter. HBK Investments L P now owns 28,000,001 shares of the company’s stock valued at $535,080,000 after acquiring an additional 7,000,000 shares during the last quarter. Dimensional Fund Advisors LP boosted its position in shares of Kenvue by 0.9% during the 1st quarter. Dimensional Fund Advisors LP now owns 22,270,175 shares of the company’s stock valued at $383,938,000 after acquiring an additional 196,981 shares during the last quarter. Finally, Amundi boosted its position in shares of Kenvue by 41.2% during the 2nd quarter. Amundi now owns 18,483,326 shares of the company’s stock valued at $353,216,000 after acquiring an additional 5,392,413 shares during the last quarter. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Kenvue Stock Performance

NYSE KVUE opened at $19.89 on Friday. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.01 and a quick ratio of 0.71. The company has a market cap of $38.19 billion, a P/E ratio of 22.86, a P/E/G ratio of 1.74 and a beta of 0.48. The stock has a 50-day moving average of $18.34 and a two-hundred day moving average of $18.26. Kenvue Inc. has a 1-year low of $14.02 and a 1-year high of $20.13.

Kenvue (NYSE:KVUE) last released its earnings results on Thursday, August 6th. The company reported $0.31 EPS for the quarter, missing the consensus estimate of $0.32 by ($0.01). Kenvue had a return on equity of 21.22% and a net margin of 10.76%. The company had revenue of $3.96 billion for the quarter, compared to analyst estimates of $3.97 billion. During the same period in the previous year, the firm earned $0.29 earnings per share. The company’s revenue for the quarter was up 3.0% compared to the same quarter last year. As a group, analysts anticipate that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, October 2nd. Investors of record on Monday, September 21st were issued a $0.21 dividend. This represents a $0.84 dividend on an annualized basis and a yield of 4.2%. The ex-dividend date of this dividend was Monday, September 21st. Kenvue’s dividend payout ratio is 96.55%.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on KVUE. Wall Street Zen lowered shares of Kenvue from a “buy” rating to a “hold” rating in a report on Saturday, August 8th. Zacks Research downgraded shares of Kenvue from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 7th. Barclays boosted their target price on shares of Kenvue from $18.00 to $19.00 and gave the company an “equal weight” rating in a report on Tuesday, July 21st. UBS Group dropped their price target on shares of Kenvue from $20.00 to $19.00 and set a “neutral” rating for the company in a research note on Tuesday, August 11th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Kenvue in a research note on Friday, September 11th. Ten equities research analysts have rated the stock with a Hold rating. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $18.43.

Kenvue Company Profile

Kenvue Inc is a consumer health company that develops, markets and sells products designed to support everyday health and personal care. Its portfolio spans over-the-counter medicines, skin health and beauty, and essential health products, serving consumers through retail, e-commerce and other distribution channels.

The company’s brands include Tylenol, Motrin, Zyrtec and Benadryl in self-care; Neutrogena, Aveeno and Clean & Clear in skin health and beauty; and Listerine, Johnson’s and OGX in oral care, baby care and hair care.